Business
Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the successful release of the first clinical batch of EVM14, a Tumor-Associated Antigen (TAA) vaccine, from its Jiashan manufacturing site, Zhejiang Province in China. This batch will support the clinical trials of EVM14 in both China and the United States (US). EVM14 received US
About this update from Everest Medicines Ltd.
[{"type":"text","content":"SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the successful release of the first clinical batch of EVM14, a Tumor-Associated Antigen (TAA) vaccine, from its Jiashan manufacturing site, Zhejiang Province in China. This batch will support the clinical trials of EVM14 in both China and the United States (US). EVM14 received US FDA clearance for its Investigational New Drug (IND) application in March 2025. This release marks another milestone in advancing Everest's proprietary mRNA platform with end-to-end capabilities spanning antigen design, lipid nanoparticle (LNP) based delivery, CMC process development and GMP manufacturing, laying a solid foundation for future pipeline progression and commercialization.","length":969,"tagName":"p"},{"type":"text","content":"The released batch was manufactured at Everest's Jiashan manufacturing site using the Company's proprietary mRNA platform, in compliance with global GMP standards.","length":171,"tagName":"p"},{"type":"text","content":"EVM14 is an off-the-shelf therapeutic mRNA cancer vaccine targeting multiple tumor-associated antigens (TAAs) and is designed to treat various squamous cell carcinomas, including non-small cell lung cancer and head and neck cancer. In preclinical studies, EVM14 induced a dose-dependent antigen-specific immune response in mice and significantly inhibited tumor growth in multiple syngeneic tumor models. Notably, EVM14 demonstrated the ability to induce immune memory and prevent tumor recurrence and metastasis, offering hope for long-term cancer-free survival. Furthermore, preclinical data demonstrated that the combination of EVM14 with immune checkpoint inhibitors (ICIs), such as PD-1 or PD-L1 inhibitors, greatly enhanced the anti-tumor activity, reduced recurrence and metastasis, and supports clinical exploration of combination therapies.","length":849,"tagName":"p"},{"type":"text","content":"In March 2025, Everest received FDA Clearance of IND Application for EVM14, marking the Company's first internally developed mRNA therapeutic vaccine to enter early-stage global clinical development. The Compa...